DEF: Charlotte's Web Announces 2026 Annual Meeting & Financing

Charlotte's Web Holdings, Inc. will hold its 2026 Annual Meeting on May 28, 2026, to vote on director elections, auditor appointment, and a major debt-to-equity transaction with British American Tobacco.

Summary

• The Company will hold its Annual General and Special Meeting virtually on May 28, 2026.
• Key agenda items include setting the number of directors at six, electing directors, appointing PKF OConnor Davies LLP as auditors, and approving a major transaction with BT DE Investments Inc. (BAT).
• The proposed transaction involves amending a C$75,341,080 convertible debenture and a concurrent US$10 million equity investment by BAT.
• The transaction will result in BAT becoming a Control Person, holding approximately 40.7% of the Company's common shares post-transaction.
• The Company is utilizing notice-and-access to deliver proxy materials electronically to reduce costs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-cautious development; while the deal solves an immediate liquidity crisis and debt overhang, it results in significant dilution and cedes substantial control to a single strategic partner.

Positives

• The transaction eliminates the Company's largest liability (C$75.3M principal debenture), significantly improving the balance sheet and leverage profile.
• The deal provides US$10 million in new capital to support the CMMI Medicare pilot program and operational growth.
• Reduces ongoing interest obligations associated with the existing convertible debenture.
• Strengthens the strategic relationship with British American Tobacco, a global consumer goods leader.

Negatives

• Significant dilution of existing shareholders, with BAT expected to hold approximately 40.7% of common shares post-transaction.
• BAT will gain significant influence over corporate actions, including director nominations and fundamental business decisions.
• The Company will incur approximately C$700,000 in transaction-related fees and expenses.
• The Company has a history of losses and no history of paying dividends.

Risks

• If the transaction is not approved, the Company may face a distressed refinancing or asset sale due to the inability to repay the debenture at maturity.
• BAT's significant voting interest may discourage future change-of-control transactions that could offer a premium to shareholders.
• The Company's future success is heavily dependent on the CMMI pilot program; if it fails, proceeds must be redirected to general operations.
• The Company is an 'emerging growth company' with reduced reporting requirements, which may limit transparency for some investors.

Future Outlook

The Company intends to use the US$10 million investment primarily to support its participation in the CMMI Medicare pilot program, with the goal of advancing its position in the US hemp CBD market and achieving EBITDA objectives.

Management Comments

• The Board believes the transaction removes a substantial liability while injecting new funding.
• The Board believes the Company will become more attractive to equity and debt investors post-transaction.
• The Company is excited to embrace virtual meeting technology to provide expanded access and cost savings.

Industry Context

StockSavvy.ai notes that this transaction reflects a broader trend of struggling cannabis and CBD companies seeking strategic partnerships with well-capitalized global consumer goods firms to survive and scale in a challenging regulatory environment.

Comparison to Industry Standards

• The Company's reliance on a single major strategic investor (BAT) is common among smaller, cash-constrained firms in the nascent CBD/cannabis sector.
• The use of notice-and-access for proxy delivery is standard practice for cost-conscious public companies.
• The governance structure, including the appointment of a BAT designee to the board, aligns with standard investor rights agreements for significant minority stakeholders.

Corporate Governance

Related Party Transactions

• Secured promissory note with Jesse Stanley and Master and A Hound Irrevocable Trust.
• Joint venture (DeFloria, Inc.) with AJNA BioSciences PBC and a BAT subsidiary.
• Consulting agreement with Jared Stanley.
• Promissory note loan to DeFloria.

Stakeholder Impact

• Shareholders face significant dilution.
• BAT gains substantial control and influence over the Company.
• The Company gains financial stability to pursue the CMMI pilot program.

Next Steps

• Hold the Annual General and Special Meeting on May 28, 2026.
• Obtain disinterested shareholder approval for the Transaction Resolution.
• Close the investment and complete the conversion of the debenture.

Key Dates

Recommendation

The transaction is a necessary survival move to clear debt, but the high dilution and loss of control warrant a hold until the Company demonstrates that the new capital can successfully drive growth in the CMMI program.

Keywords

Charlotte's Web, CWEB, CBD, British American Tobacco, Convertible Debenture, Proxy Statement, Equity Financing, Corporate Governance